$ARCT
Arcturus Therapeutics Holdings Inc.

2021 Q1 Form 10-Q Financial Statement

#000156459021026113 Filed on May 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $2.127M $2.646M
YoY Change -19.61% -39.17%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.740M $4.190M
YoY Change 132.46% 18.7%
% of Gross Profit
Research & Development $50.05M $7.917M
YoY Change 532.18% 8.1%
% of Gross Profit
Depreciation & Amortization $310.0K $180.0K
YoY Change 72.22% 5.88%
% of Gross Profit
Operating Expenses $59.79M $12.11M
YoY Change 393.83% 11.51%
Operating Profit -$57.67M -$9.462M
YoY Change 509.45% 45.39%
Interest Expense $1.320M -$320.0K
YoY Change -512.5% -15.79%
% of Operating Profit
Other Income/Expense, Net -$358.0K -$152.0K
YoY Change 135.53% 72.73%
Pretax Income -$56.35M -$9.780M
YoY Change 476.18% 42.15%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$56.35M -$9.777M
YoY Change 476.31% 42.02%
Net Earnings / Revenue -2649.08% -369.5%
Basic Earnings Per Share
Diluted Earnings Per Share -$2.147M -$673.6K
COMMON SHARES
Basic Shares Outstanding 26.28M 15.14M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $466.8M $59.50M
YoY Change 684.54% 90.71%
Cash & Equivalents $466.8M $59.47M
Short-Term Investments
Other Short-Term Assets $1.200M $593.0K
YoY Change 102.36% -34.11%
Inventory
Prepaid Expenses $1.344M
Receivables $2.000M $2.351M
Other Receivables $0.00 $0.00
Total Short-Term Assets $470.0M $63.76M
YoY Change 637.15% 74.2%
LONG-TERM ASSETS
Property, Plant & Equipment $3.427M $2.571M
YoY Change 33.29% -66.61%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $1.200M $100.0K
YoY Change 1100.0%
Other Assets $100.0K $100.0K
YoY Change 0.0% 0.0%
Total Long-Term Assets $11.50M $8.345M
YoY Change 37.81% 6.99%
TOTAL ASSETS
Total Short-Term Assets $470.0M $63.76M
Total Long-Term Assets $11.50M $8.345M
Total Assets $481.5M $72.10M
YoY Change 567.79% 62.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.600M $3.779M
YoY Change 48.19% -7.83%
Accrued Expenses $29.80M $9.775M
YoY Change 204.86% 443.06%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $3.125M
YoY Change
Total Short-Term Liabilities $53.30M $21.65M
YoY Change 146.19% 48.29%
LONG-TERM LIABILITIES
Long-Term Debt $58.10M $15.03M
YoY Change 286.61% 51.8%
Other Long-Term Liabilities $358.0K $18.40M
YoY Change -98.05% 36.3%
Total Long-Term Liabilities $358.0K $15.03M
YoY Change -97.62% -35.78%
TOTAL LIABILITIES
Total Short-Term Liabilities $53.30M $21.65M
Total Long-Term Liabilities $358.0K $15.03M
Total Liabilities $128.9M $55.12M
YoY Change 133.84% 44.68%
SHAREHOLDERS EQUITY
Retained Earnings -$200.2M -$81.45M
YoY Change 145.81%
Common Stock $15.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $352.6M $16.98M
YoY Change
Total Liabilities & Shareholders Equity $481.5M $72.10M
YoY Change 567.79% 62.4%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$56.35M -$9.777M
YoY Change 476.31% 42.02%
Depreciation, Depletion And Amortization $310.0K $180.0K
YoY Change 72.22% 5.88%
Cash From Operating Activities -$42.95M -$11.86M
YoY Change 262.2% 119.15%
INVESTING ACTIVITIES
Capital Expenditures $118.0K $142.0K
YoY Change -16.9% 82.05%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$118.0K -$142.0K
YoY Change -16.9% 82.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 47.01M 118.0K
YoY Change 39740.68%
NET CHANGE
Cash From Operating Activities -42.95M -11.86M
Cash From Investing Activities -118.0K -142.0K
Cash From Financing Activities 47.01M 118.0K
Net Change In Cash 3.944M -11.88M
YoY Change -133.19% 116.47%
FREE CASH FLOW
Cash From Operating Activities -$42.95M -$11.86M
Capital Expenditures $118.0K $142.0K
Free Cash Flow -$43.07M -$12.00M
YoY Change 258.9% 118.62%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccruedLiabilitiesCurrent
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
352607000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
25792000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-9777000
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
358000
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccruedLiabilitiesCurrent
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
430000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-152000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-9777000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.67
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14521000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-56346000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9777000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
396553000
CY2021Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
5000000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6987000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
413000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-56346000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
307000
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
182000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
6987000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
849000
CY2021Q1 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
5000000
CY2021Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1248000
CY2020Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-163000
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
440000
CY2021Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-696000
CY2020Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-274000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-118000
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
172000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1619000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1179000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5415000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2276000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
7143000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1746000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71460000
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1371000
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1668000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-42950000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11858000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
118000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
142000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-118000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-142000
CY2021Q1 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
46599000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
413000
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
118000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
47012000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
118000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3944000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-11882000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
463002000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
466946000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
59578000
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
169000
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
228000
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1828000
CY2020Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
674000
CY2021Q1 arct Acquisition Of Research And Development In Process Through Issuance Of Common Stock
AcquisitionOfResearchAndDevelopmentInProcessThroughIssuanceOfCommonStock
5000000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
238000
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
262000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-200200000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-143800000
CY2021Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
466839000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59471000
CY2021Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
107000
CY2020Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
107000
CY2021Q1 us-gaap Dividends
Dividends
0
CY2020Q1 us-gaap Dividends
Dividends
0
CY2020Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
2125000
CY2021Q1 arct Contract With Customer Asset Additions For Revenue Recognized
ContractWithCustomerAssetAdditionsForRevenueRecognized
756000
CY2021Q1 arct Contract With Customer Asset Deductions For Cash Collections
ContractWithCustomerAssetDeductionsForCashCollections
-874000
CY2021Q1 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
2007000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
30620000
CY2021Q1 arct Contract With Customer Liability Additions For Advanced Billings
ContractWithCustomerLiabilityAdditionsForAdvancedBillings
756000
CY2021Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-2127000
CY2021Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
29249000
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2127000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2646000
CY2021Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6797000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6441000
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3370000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3063000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3427000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3378000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
CY2021Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
3125000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1250000
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3834000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2097000
CY2021Q1 arct Accrued Cystic Fibrosis Foundation Liability
AccruedCysticFibrosisFoundationLiability
5913000
CY2020Q4 arct Accrued Cystic Fibrosis Foundation Liability
AccruedCysticFibrosisFoundationLiability
6585000
CY2020Q4 arct Accrued Singapore Economic Development Board Liability
AccruedSingaporeEconomicDevelopmentBoardLiability
1761000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1443000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1630000
CY2021Q1 arct Clinical Accruals Current
ClinicalAccrualsCurrent
7217000
CY2020Q4 arct Clinical Accruals Current
ClinicalAccrualsCurrent
4067000
CY2021Q1 arct Other Accrued Research And Development Expenses
OtherAccruedResearchAndDevelopmentExpenses
8268000
CY2020Q4 arct Other Accrued Research And Development Expenses
OtherAccruedResearchAndDevelopmentExpenses
3249000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
29800000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20639000
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
1250000
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
7500000
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
6550000
CY2021Q1 us-gaap Long Term Debt
LongTermDebt
15300000
CY2021Q1 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
200000
CY2020Q1 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
300000
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1320390
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
316957
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6987000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
849000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P13M
CY2020Q1 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
one twelve-month period.
CY2021Q1 arct Monthly Base Rent
MonthlyBaseRent
11000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1534000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1987000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2185000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2250000
CY2021Q1 arct Lessee Operating Lease Liability Payments Due After Year Three
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree
521000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
8477000
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1324000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
7153000
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.084
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
400000
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
400000

Files In Submission

Name View Source Status
0001564590-21-026113-index-headers.html Edgar Link pending
0001564590-21-026113-index.html Edgar Link pending
0001564590-21-026113.txt Edgar Link pending
0001564590-21-026113-xbrl.zip Edgar Link pending
arct-10q_20210331.htm Edgar Link pending
arct-10q_20210331_htm.xml Edgar Link completed
arct-20210331.xsd Edgar Link pending
arct-20210331_cal.xml Edgar Link unprocessable
arct-20210331_def.xml Edgar Link unprocessable
arct-20210331_lab.xml Edgar Link unprocessable
arct-20210331_pre.xml Edgar Link unprocessable
arct-ex311_7.htm Edgar Link pending
arct-ex312_6.htm Edgar Link pending
arct-ex321_9.htm Edgar Link pending
arct-ex322_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending